EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Factors Associated With Semaglutide Initiation Among Adults With Obesity

Meghan I Podolsky, Rafeya Raquib, Paul R Shafer, Katherine Hempstead, Randall P Ellis, Andrew C Stokes

JAMA Network Open · 21.01.2025 · 8 (1) · e2455222

DOI: 10.1001/jamanetworkopen.2024.55222 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA Network Open, online erschienen am 21.01.2025. Verfasst von Meghan I Podolsky und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.

Objective

To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes. Design, Setting, and Participants This retrospective observational cohort study used data from the Merative MarketScan Commercial Claims and Encounters Database and included adults in the US aged 18 years or older with a first diagnosis of obesity in an outpatient or inpatient setting between June 5, 2021, and July 1, 2022. Inclusion criteria were no prior antiobesity medication, GLP-1, bariatric surgery, or diabetes-related claim in the 12 months prior to obesity diagnosis, and continuous enrollment in the 12 months preceding and 6 months following obesity diagnosis. Analysis was conducted from February to November 2024. Exposures Medication classes prescribed, clinical diagnoses, and sociodemographic factors. Exposures were identified within the 12 months prior to obesity diagnosis. Main Outcomes and Measures Factors associated with incident semaglutide prescription within 6 months after obesity diagnoses were identified using a 10-fold cross-classified random forest model. The top 20 features of the model feature importance list were ranked in a Shapley Additive Explanations plot and used in a multivariable logistic regression model to quantify associations with semaglutide initiation.

Results

In this study of 97 456 individuals, 58 124 (59.6%) were female, 26 582 (27.3%) were aged 45 to 54 years, 50 705 (52.0%) resided in the South region, and 49 390 (50.7%) were covered by preferred provider organization plans. Of all participants, 1963 (2.0%) initiated semaglutide within 6 months of their initial obesity diagnosis. The random forest model had an area under the receiver operating characteristic curve of 0.71 (95% CI, 0.69-0.74). The most important exposures identified via Shapley Additive Explanations were sex, use of antidepressants, and employer industry. The top 20 factors were used in the logistic regression model, and significant associations were found with semaglutide initiation, including being female (adjusted odds ratio [aOR], 2.30; 95% CI, 2.05-2.58), use of certain medication classes including antidepressants (aOR,1.62; 95% CI, 1.46-1.78), and being covered by a point-of-service plan (aOR, 1.78; 95% C, 1.42-2.22). Conclusions and Relevance This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those without diabetes. These findings suggest that insurance plan type and structure may be a crucial intervention point for improving equity in obesity treatment access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesObesityAnti-Obesity AgentsHumansFemaleMaleAdultMiddle AgedRetrospective StudiesUnited StatesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Substanzen

Glucagon-Like PeptidesAnti-Obesity AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.
  • Now with: Bristol Meyers Squibb, Princeton, New Jersey.
  • Department of Health Law, Policy, and Management, School of Public Health, Boston University, Boston, Massachusetts.
  • The Robert Wood Johnson Foundation, Princeton, New Jersey.
  • Department of Economics, Boston University, Boston, Massachusetts.

Zitieren

APA

Podolsky, M. I., Raquib, R., Shafer, P. R., Hempstead, K., Ellis, R. P., & Stokes, A. C. (2025). Factors Associated With Semaglutide Initiation Among Adults With Obesity. JAMA Network Open, 8(1), e2455222. https://doi.org/10.1001/jamanetworkopen.2024.55222

Vancouver

Podolsky MI, Raquib R, Shafer PR, Hempstead K, Ellis RP, Stokes AC. Factors Associated With Semaglutide Initiation Among Adults With Obesity. JAMA Network Open. 2025;8(1):e2455222. doi:10.1001/jamanetworkopen.2024.55222

BibTeX
@article{Podolsky2025,
  author = {Podolsky, Meghan I and Raquib, Rafeya and Shafer, Paul R and Hempstead, Katherine and Ellis, Randall P and Stokes, Andrew C},
  title = {Factors Associated With Semaglutide Initiation Among Adults With Obesity},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {1},
  pages = {e2455222},
  doi = {10.1001/jamanetworkopen.2024.55222}
}
Kostenlos starten →